Citigroup
APVO icon

Citigroup’s Aptevo Therapeutics APVO Stock Holding History

Citigroup’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,756
Closed -$26K – 5935
2025
Q4 		$26K Buy
2,756
+2,752
+68,800% +$65.5K ﹤0.01% 4796
2025
Q3 		$107 Buy
+4
New +$161 ﹤0.01% 5805
2024
Q1 		– Hold
0
– -$2 – 5631
2023
Q4 		– Hold
0
– – – 5660
2023
Q3 		– Hold
0
– – – 5636
2023
Q2 		– Hold
0
– – – 5508
2023
Q1 		– Hold
0
– – – 5373
2022
Q4 		– Hold
0
– – – 5694
2022
Q3 		– Hold
0
– – – 5804
2022
Q2 		– Hold
0
– – – 6212
2022
Q1 		– Hold
0
– – – 6290
2021
Q4 		– Hold
0
– – – 5805
2021
Q3 		– Hold
0
– – – 5746
2021
Q2 		– Hold
0
– – – 6112
2021
Q1 		– Hold
0
– -$35K – 6225
2020
Q4 		– Hold
0
– – – 6278
2017
Q2 		– Hold
0
– – – 7331
2017
Q1 		– Hold
0
– – – 7175
2016
Q4 		– Hold
0
– – – 6239
2016
Q3 		– Hold
0
– – – 6858

Other funds holding APVO

GSA Capital Partners
GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Citigroup's APVO Position: Q1 2026 in Review

Citigroup sold out of Aptevo Therapeutics (APVO) in Q1 2026, closing a stake of 2,756 shares — an estimated $26K sold.

Citigroup first reported a position in APVO in Q3 2025 and held it in 2 quarters. The position peaked at $26K in Q4 2025. 9 funds tracked by Wall St. Rank hold APVO as of Q1 2026.

  • Citigroup reported no remaining Aptevo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 2,756 Aptevo Therapeutics shares in Q1 2026, an estimated $26K.
  • Citigroup first reported a position in Aptevo Therapeutics in Q3 2025 and held it in 2 quarters.
  • Citigroup's Aptevo Therapeutics position peaked at $26K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.